Associated Papers
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
Zhang W et al.
Npj Precision Oncology, 2022
35739249 (PubMed )
Supplement: 41698_2022_292_MOESM1_ESM.xlsx › Supplementary_Data_1
Select a paper to view details